Lipoxygenase Inhibitors
2 drugsAbout Lipoxygenase
Lipoxygenases (LOX) are non-heme iron dioxygenases that oxidize polyunsaturated fatty acids, producing signaling molecules involved in inflammation.
Lipoxygenases are attractive drug targets in immunology due to the involvement of their products in inflammatory pathways; however, there is currently no genetic evidence directly linking them to specific diseases.
Two FDA-approved drugs, COLAZAL and BALSALAZIDE DISODIUM, target lipoxygenases as small molecules for inflammatory bowel disease.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Basal Cell Carcinoma with only 1 trials.
Top Drugs
ZYDUS LIFESCIENCES and VALEANT PHARMS INTL are the companies with approved drugs.
The market is not highly competitive, suggesting opportunities for new entrants with novel lipoxygenase inhibitors.
Drug Modality Landscape
Modalities
Routes of Administration
Lipoxygenase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like antibodies or biologics to differentiate from existing therapies.
Clinical Trials 18 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 7 | 1 | 1 | 88% |
| Phase 2 | 3 | 2 | 0 | 1 | 100% |
| Phase 3 | 4 | 3 | 1 | 0 | 75% |
| Phase 4 | 2 | 1 | 1 | 0 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2000 - 2007)
The first drug was approved in 2000, and the most recent in 2007.
The approval timeline shows a stagnant market, indicating potential for innovation in this therapeutic area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (10 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 11 clinical trials targeting Lipoxygenase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities